Evidence map›Paper›PMID 39964549›Full record

ArticleCerebellum (London, England)2025

Differential Protective Effects of Edaravone in Cerebellar and Hippocampal Ischemic Injury Models.

Jens Dickmeiß, Yoshiyuki Henning, Sarah Stahlke, Thomas Weber, Carsten Theiss, Veronika Matschke

Abstract read
In one paragraph

Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jens DickmeißDepartment of Cytology, Institute of Anatomy, Medical Faculty, Ruhr-University Bochum, Bochum, Germany.
Yoshiyuki HenningInstitute of Physiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sarah StahlkeDepartment of Cytology, Institute of Anatomy, Medical Faculty, Ruhr-University Bochum, Bochum, Germany.
Thomas WeberDepartment of Anesthesiology and Intensive Care Medicine, Ruhr University Bochum, St. Josef Hospital, D-44791, Bochum, Germany.
Carsten TheissDepartment of Cytology, Institute of Anatomy, Medical Faculty, Ruhr-University Bochum, Bochum, Germany.
Veronika MatschkeDepartment of Cytology, Institute of Anatomy, Medical Faculty, Ruhr-University Bochum, Bochum, Germany. veronika.matschke@rub.de.ORCID http://orcid.org/0000-0001-9717-4485

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke is a leading cause of mortality and disability, with cerebellar strokes posing severe complications such as herniation and brainstem compression. Edaravone, a radical scavenger known for reducing oxidative stress, has shown neuroprotective effects in cerebral strokes, but its impact on cerebellar strokes remains unclear. This study investigates Edaravone's protective properties in organotypic slice cultures of rat cerebellum and hippocampus, employing an oxygen-glucose deprivation (OGD) model to simulate ischemic stroke. The hippocampus served as comparative structure due to its high hypoxia sensitivity. Our results confirmed effective hypoxic induction with increases in HIF-1α and HIF-2α expression. Edaravone significantly reduced lactate dehydrogenase (LDH) levels, indicating diminished cellular damage, with cerebellar tissues showing greater vulnerability. Additionally, Edaravone reduced reactive oxygen species (ROS) in both tissues, though its efficacy may be limited by higher oxidative stress in cerebellar cultures. Seahorse XF analysis revealed that Edaravone preserved mitochondrial respiration and tissue integrity in cerebellar and hippocampal slice cultures. However, Edaravone was more effective in preserving mitochondrial respiration in hippocampal slices, suggesting that OGD-induced damage is more severe in cerebellar tissue. In conclusion, Edaravone demonstrates significant cell protective effects in both cerebellar and hippocampal tissues under OGD conditions, preserving tissue integrity and enhancing mitochondrial function in a tissue-dependent manner. These findings suggest Edaravone as a promising therapeutic candidate for cerebellar stroke. Further in vivo studies are required to assess its full clinical potential.

Indexed as

AntipyrineBrain IschemiaCerebellumEdaravoneHippocampusNeuroprotective AgentsAnimalsDisease Models, AnimalFree Radical ScavengersGlucoseMaleMitochondriaOrgan Culture TechniquesOxidative StressRatsRats, Sprague-DawleyAntipyrineEdaravoneFree Radical ScavengersGlucoseNeuroprotective AgentsReactive Oxygen SpeciesBrain damageCell deathHypoxia chamberIschemiaMitochondriaOrganotypic slice culturesOxygen consumption rate (OCR)Seahorse XFStroke

Identifiers

PMID39964549
PMCPMC11835913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.